Menopause
Conference Coverage
Estetrol safely limited menopause symptoms in a phase 2b study
E4 has “a remarkably safe profile,” which Dr. Wulf H. Utian describes as “the first natural oral estrogen with the safety profile of a transdermal...
Conference Coverage
No signal for CV, breast effects with bioidentical vaginal estrogen for dyspareunia
Low-dose vaginal softgel is approved for treating moderate to severe dyspareunia associated with menopause.
Conference Coverage
For dyspareunia, intravaginal prasterone may work best soon after menopause
Age and previous hormone replacement therapy did not influence prasterone’s efficacy in treating dyspareunia.
From the Journals
No falls, fractures, or bone density benefits from vitamin D supplements
Vitamin D supplementation does not appear to reduce the risk of falls or fracture or to improve bone mineral density.
Conference Coverage
Zoledronate reduces fracture risk in elderly women with osteopenia
Women with osteopenia who received intravenous zoledronate had a significantly lower risk of fractures.
Conference Coverage
Migraine and menopause: Longitudinal study shows what to expect
From the Journals
High testosterone in postmenopausal women may add CVD risk
Having more testosterone than estrogen may spell heart disease after menopause.
Video
VIDEO: Stem cells may reverse premature menopause, restore fertility
CHICAGO – In addition to bringing estrogen levels closer to normal, the treatment diminishes other menopause symptoms.
From the Journals
Menopause accelerates RA functional decline
Findings were based on surveys of over 8,000 women.
From the Journals
Don’t choose hormones to protect postmenopausal women
The USPSTF has issued a recommendation against using estrogen or estrogen plus progestin to prevent chronic conditions in postmenopausal women.
Opinion
Strategies to evaluate postmenopausal bleeding
Pros and cons of blind and targeted sampling.